After FD comes CD

Cephalon's upside earnings surprise last week illustrates the dilemmas caused by the SEC's Regulation FD, put in place last October to curb selective disclosure of material information.

The company elected to wait until its third quarter earnings conference call to disclose that it had seen a higher than expected run rate of sales for its narcolepsy drug

Read the full 574 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE